Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 3 1Phase 2/3 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 2Melanoma 1Cytopenia 1

Interventions

Azacitidine 38Cytarabine 22venetoclax 19fludarabine phosphate 18fludarabine 18Cyclophosphamide 18Peripheral Blood Stem Cell Transplantation 15Tacrolimus 14Filgrastim 13Decitabine 13Mycophenolic Acid 12Busulfan 12Whole-Body Irradiation 11Melphalan 11Methotrexate 10Cyclosporine 10Antilymphocyte Serum 8Stem Cell Transplantation 7Alemtuzumab 7decitabine and cedazuridine drug combination 6Granulocyte Colony-Stimulating Factor 6Clofarabine 6AP 1903 reagent 6Thiotepa 5Rituximab 5Idarubicin 5quizartinib 4Tretinoin 4Sirolimus 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Myelodysplastic Syndromes × cedazuridine × Clear all
NCT05918055 2025-12-02

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
130 enrolled 34 charts 1 FDA
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡